Cargando…

Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series

The use of ketamine infusion for sedation/analgesia in patients receiving extracorporeal membrane oxygenation (ECMO) therapy has not been described. The aims of this retrospective cohort study were to explore whether ketamine infusion for patients requiring ECMO therapy was associated with altered R...

Descripción completa

Detalles Bibliográficos
Autores principales: Tellor, Bethany, Shin, Nicole, Graetz, Thomas J., Avidan, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536611/
https://www.ncbi.nlm.nih.gov/pubmed/26309726
http://dx.doi.org/10.12688/f1000research.6006.1
_version_ 1782385765978734592
author Tellor, Bethany
Shin, Nicole
Graetz, Thomas J.
Avidan, Michael S.
author_facet Tellor, Bethany
Shin, Nicole
Graetz, Thomas J.
Avidan, Michael S.
author_sort Tellor, Bethany
collection PubMed
description The use of ketamine infusion for sedation/analgesia in patients receiving extracorporeal membrane oxygenation (ECMO) therapy has not been described. The aims of this retrospective cohort study were to explore whether ketamine infusion for patients requiring ECMO therapy was associated with altered RASS scores, decreased concurrent sedative or opioid use, or with changes in vasopressor requirements.  All patients on ECMO who received ketamine infusions in addition to sedative and/or opioid infusions between December 2013 and October 2014 at Barnes-Jewish Hospital in St. Louis were retrospectively identified. Patient characteristics and process of care data were collected. A total of 26 ECMO patients receiving ketamine infusion were identified. The median (inter quartile range [range]) age was 40 years (30-52 [25-66]) with 62% male. The median starting infusion rate of ketamine was 50 mg/hr (30-50 [6-150]) and it was continued for a median duration of 9 days (4-14 [0.2-21]). Prior to ketamine, 14/26 patients were receiving vasopressor infusions to maintain hemodynamic stability. Ketamine initiation was associated with a decrease in vasopressor requirement in 11/26  patients within two hours, and 0/26 required an increase (p<0.001). All patients were receiving sedative and/or opioid infusions at the time of ketamine initiation; 9/26 had a decrease in these infusions within two hours of ketamine initiation, and 1/26 had an increase (p=0.02; odds ratio for decrease to increase = 9; 95% CI, 1.14 to 71.04). The median (IQR[range]) RASS score 24 hours before ketamine initiation was -4 (-3 to -5, [0 to -5]) and after ketamine was -4 (-3 to -4 [-1 to -5]) ( P = 0.614). Ketamine infusion can be used as an adjunctive sedative agent in patients receiving ECMO and may decrease concurrent sedative and/or opioid infusions without altering RASS scores. The hemodynamic effects of ketamine may provide the benefit of decreasing vasopressor requirements.
format Online
Article
Text
id pubmed-4536611
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-45366112015-08-24 Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series Tellor, Bethany Shin, Nicole Graetz, Thomas J. Avidan, Michael S. F1000Res Research Article The use of ketamine infusion for sedation/analgesia in patients receiving extracorporeal membrane oxygenation (ECMO) therapy has not been described. The aims of this retrospective cohort study were to explore whether ketamine infusion for patients requiring ECMO therapy was associated with altered RASS scores, decreased concurrent sedative or opioid use, or with changes in vasopressor requirements.  All patients on ECMO who received ketamine infusions in addition to sedative and/or opioid infusions between December 2013 and October 2014 at Barnes-Jewish Hospital in St. Louis were retrospectively identified. Patient characteristics and process of care data were collected. A total of 26 ECMO patients receiving ketamine infusion were identified. The median (inter quartile range [range]) age was 40 years (30-52 [25-66]) with 62% male. The median starting infusion rate of ketamine was 50 mg/hr (30-50 [6-150]) and it was continued for a median duration of 9 days (4-14 [0.2-21]). Prior to ketamine, 14/26 patients were receiving vasopressor infusions to maintain hemodynamic stability. Ketamine initiation was associated with a decrease in vasopressor requirement in 11/26  patients within two hours, and 0/26 required an increase (p<0.001). All patients were receiving sedative and/or opioid infusions at the time of ketamine initiation; 9/26 had a decrease in these infusions within two hours of ketamine initiation, and 1/26 had an increase (p=0.02; odds ratio for decrease to increase = 9; 95% CI, 1.14 to 71.04). The median (IQR[range]) RASS score 24 hours before ketamine initiation was -4 (-3 to -5, [0 to -5]) and after ketamine was -4 (-3 to -4 [-1 to -5]) ( P = 0.614). Ketamine infusion can be used as an adjunctive sedative agent in patients receiving ECMO and may decrease concurrent sedative and/or opioid infusions without altering RASS scores. The hemodynamic effects of ketamine may provide the benefit of decreasing vasopressor requirements. F1000Research 2015-01-16 /pmc/articles/PMC4536611/ /pubmed/26309726 http://dx.doi.org/10.12688/f1000research.6006.1 Text en Copyright: © 2015 Tellor B et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/publicdomain/zero/1.0/ Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
spellingShingle Research Article
Tellor, Bethany
Shin, Nicole
Graetz, Thomas J.
Avidan, Michael S.
Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series
title Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series
title_full Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series
title_fullStr Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series
title_full_unstemmed Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series
title_short Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series
title_sort ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536611/
https://www.ncbi.nlm.nih.gov/pubmed/26309726
http://dx.doi.org/10.12688/f1000research.6006.1
work_keys_str_mv AT tellorbethany ketamineinfusionforpatientsreceivingextracorporealmembraneoxygenationsupportacaseseries
AT shinnicole ketamineinfusionforpatientsreceivingextracorporealmembraneoxygenationsupportacaseseries
AT graetzthomasj ketamineinfusionforpatientsreceivingextracorporealmembraneoxygenationsupportacaseseries
AT avidanmichaels ketamineinfusionforpatientsreceivingextracorporealmembraneoxygenationsupportacaseseries